The accuracy of our novel sequencing approach has the potential to advance cancer diagnostics, drive higher fidelity for single-cell applications, and broadly enable clinical sequencing—even in regions of the genome prone to sequencing errors. By focusing on the binding event, our SBB technology is able to provide an unsurpassed precision of nucleotide and DNA matching by leveraging the polymerase’s natural matching ability. Depending upon the application, our SBB approach also has the potential to deliver lower cost, decreased runtime, and more samples per run.
